Abstract
Despite the success of responsive neurostimulation (RNS) for epilepsy, clinical outcomes vary significantly and are hard to predict. The ability to forecast clinical response to RNS therapy before device implantation would improve patient selection for RNS surgery and could prevent a costly and ineffective intervention. Determining and validating biomarkers predictive of RNS response is difficult, however, due to the heterogeneity of the RNS patient population and clinical procedures; large, multi-center datasets are needed to quantify patient variability and to account for stereotypy in the treatment paradigm of any one center. Here we use a distributed, cloud-based pipeline to analyze a federated dataset of intracranial EEG recordings, collected prior to RNS surgery, from a retrospective cohort of 30 patients across three major epilepsy centers. Based on recent work modelling the controllability of distributed brain networks, we hypothesize that broader brain network connectivity, beyond the seizure onset zone, can predict RNS response. We demonstrate how intracranial EEG recordings can be leveraged through network analysis to uncover biomarkers that predict response to RNS therapy. Our findings suggest that peri-ictal changes in synchronizability, a global network metric shown to accurately predict outcome from resective epilepsy surgery, can distinguish between good and poor RNS responders under the current RNS therapy guidelines (area under the receiver operating characteristic curve of 0.75). Furthermore, this study also provides a proof-of-concept roadmap for multicenter collaboration where practical considerations impede sharing datasets fully across centers.
Competing Interest Statement
V.R.R. has served as a paid consultant to NeuroPace, Inc., manufacturer of the RNS System, but declares no targeted compensation for this work. D.F. receives salary support for consulting and clinical trial related activities performed on behalf of The Epilepsy Study Consortium, a non-profit organization. Dr. Friedman receives no personal income for these activities. Within the past two years, The Epilepsy Study Consortium received payments for research services performed by Dr. Friedman from: BioXell, Biogen, Cerebral Therapeutics, Cerevel, Crossject, Engage Pharmaceuticals, Eisai, Lundbeck, SK Life Science, Xenon, and Zynerba. He has also served as a paid consultant for Eisai and Neurelis Pharmaceuticals. He has received travel support from Medtronic, Eisai and the Epilepsy Foundation. He has received research support from the Epilepsy Foundation, Empatica, Epitel, and NeuroPace unrelated to this study. He serves on the scientific advisory board for Receptor Life Sciences. He holds equity interests in Neuroview Technology and Receptor Life Sciences. He received royalty income from Oxford University Press.
Funding Statement
This work is supported by the NINDS UH3NS 95495-4 & NINDS R01NS099348 grants, the Pennsylvania Tobacco Fund, Johnathan Rothberg, and the Mirowski Family Foundation. J.B. acknowledges funding from NIH 6T32NS091006. ANK acknowledges research support from the Citizens United for Research in Epilepsy: Taking Flight Award. V.R.R. is supported by the Ernest Gallo Foundation Distinguished Professorship at the University of California, San Francisco. NYU receives a fixed amount from the Epilepsy Study Consortium towards Dr. Friedman's salary.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data from these evaluations were collected solely for clinical use and incorporated into this study retrospectively. Data collection for research purposes at HUP was approved by the HUP Institutional Review Board under the Collaborative and IEEG protocols; all HUP subjects provided consent to have their full-length intracranial EEG recordings and anonymized imaging and metadata publicly released on the ieeg.org portal, an open-source online repository for electrophysiologic studies. The NYU Langone Institutional Review Board granted approval for data collection and allowed that informed consent could be waived for studies involving sharing of deidentified EEG and imaging data. Finally, data collection at UCSF was approved by the UCSF Committee on Human Research, which ruled that informed consent could be waived for studies involving sharing of deidentified EEG and imaging data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We share all functional connectivity networks and synchronizability curves derived from iEEG recordings obtained during a patient's stay in the epilepsy monitoring unit on the free and HIPPA-secure web portal ieeg.org. The code used for generating functional networks and calculating synchronizability is freely available at https://github.com/akhambhati/Echobase.
Abbreviations
- AUC
- area under the ROC curve
- ECoG
- electrocorticography
- EMU
- epilepsy monitoring unit
- RNS
- responsive neurostimulation
- ROC
- receiver operating characteristic
- SOZ
- seizure onset zone
